
Recursion (NASDAQ: RXRX), a leading TechBio company decoding biology to industrialize drug discovery, today announced the appointment of David Mauro, M.D., Ph.D, as Chief Medical Officer. In this key role, Mauro will orchestrate and curate Recursion’s pipeline, including the five programs currently in the clinic.
David is a broadly accomplished executive. His history manifests a pleasing combination of strategic vision with a tactile, detailed, and disciplined sense of what is required to develop a drug. Mauro’s extensive professional background includes the selection and cultivation of large and small molecules, effectiveness across modalities in oncology, and successful leadership in both large and small organizations.
Mauro brings to Recursion over 20 years in oncology R&D. His notable accomplishments include guiding the translational, preliminary, and later stages of development for more than 25 IND candidates over the past decade. His prior roles have involved serving as the Chief Medical Officer for Codiak BioSciences, Checkmate Pharmaceuticals, Prelude Therapeutics, and Advaxis. Previously, Dr. Mauro has also held executive roles at Merck and Bristol Myers Squibb.
Mauro received a B.S. in Biochemistry from Cornell University and an M.D./Ph.D. from Temple University. He completed his residency in anatomic pathology at the National Cancer Institute.
Read more about Occam's work with Recursion in our case study.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.